Performance | Hansoh Pharmaceutical Profits Increased by 27% Last Year, Dividend of 20 Cents

SighingCashier · 2026-03-29T14:20:32+00:00

Hansoh Pharmaceutical (03692) announced that for the fiscal year ending last year, attributable net profit to shareholders was 5.555 billion yuan ( RMB, same below ), an increase of 27.07%; earnings per share were 0.93 yuan.The final dividend is 20 HK cents, with a total of 43.16 cents including the interim dividend for the full year.During the period, revenue was 15.028 billion yuan, an increase of 22.57% year-on-year. Sales of innovative drugs and collaborative products amounted to 12.354 billion yuan, a year-on-year growth of 30.4%. R&D expenses were approximately 3.358 billion yuan, up 24.3% year-on-year.

SighingCashier

2026-03-29 14:20:32

Hansen Pharmaceutical (03692) announced its annual results for the year ending last year, with a net profit attributable to shareholders of 5.555 billion yuan (RMB, same below), an increase of 27.07%; earnings per share of 0.93 yuan.

A final dividend of 20 Hong Kong cents will be distributed, along with an interim dividend, totaling 43.16 cents for the year.

During the period, revenue was 15.028 billion yuan, an increase of 22.57% year-on-year. Revenue from innovative drugs and cooperative products was 12.354 billion yuan, an increase of 30.4% year-on-year. Research and development expenses were approximately 3.358 billion yuan, an increase of 24.3% year-on-year.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes